SciClone Pharmaceuticals, Inc. Announces Presentation Of ZADAXIN Phase 2 Liver Cancer Data At Shanghai-Hong Kong International Liver Congress

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the presentation of data from its phase 2 hepatocellular carcinoma, or primary liver cancer, trial at the Shanghai-Hong Kong International Liver Congress. Dr. Robert Gish, M.D., Medical Director, Liver Transplant Program at California Pacific Medical Center, and principal investigator of this trial presented these data in a plenary session today in Shanghai, China. SciClone reported these data in late 2005, which showed a median survival of 994 days for the 12 patients who received ZADAXIN plus trans-arterial chemoembolization (TACE), compared with a median survival of only 399 days for the 13 patients who only received TACE.